243 related articles for article (PubMed ID: 19020388)
1. Patients with craniopharyngiomas: therapeutical difficulties with growth hormone.
Cannavò S; Marini F; Trimarchi F
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):56-60. PubMed ID: 19020388
[TBL] [Abstract][Full Text] [Related]
2. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P;
Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692
[TBL] [Abstract][Full Text] [Related]
3. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
Feldt-Rasmussen U; Wilton P; Jonsson P; ;
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
[TBL] [Abstract][Full Text] [Related]
4. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma.
Kendall-Taylor P; Jönsson PJ; Abs R; Erfurth EM; Koltowska-Häggström M; Price DA; Verhelst J
Eur J Endocrinol; 2005 Apr; 152(4):557-67. PubMed ID: 15817911
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
[TBL] [Abstract][Full Text] [Related]
6. Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone Replacement.
Yuen KCJ; Mattsson AF; Burman P; Erfurth EM; Camacho-Hubner C; Fox JL; Verhelst J; Geffner ME; Abs R
J Clin Endocrinol Metab; 2018 Feb; 103(2):768-777. PubMed ID: 29029108
[TBL] [Abstract][Full Text] [Related]
7. Hypopituitarism oddities: craniopharyngiomas.
Karavitaki N
Horm Res; 2007; 68 Suppl 5():151-3. PubMed ID: 18174734
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database.
Kreitschmann-Andermahr I; Poll EM; Reineke A; Gilsbach JM; Brabant G; Buchfelder M; Fassbender W; Faust M; Kann PH; Wallaschofski H
Growth Horm IGF Res; 2008 Dec; 18(6):472-8. PubMed ID: 18829359
[TBL] [Abstract][Full Text] [Related]
9. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database.
Attanasio AF; Bates PC; Ho KK; Webb SM; Ross RJ; Strasburger CJ; Bouillon R; Crowe B; Selander K; Valle D; Lamberts SW;
J Clin Endocrinol Metab; 2002 Apr; 87(4):1600-6. PubMed ID: 11932289
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.
Yuen KC; Koltowska-Häggström M; Cook DM; Fox JL; Jönsson PJ; Geffner ME; Abs R
Eur J Endocrinol; 2013 Oct; 169(4):511-9. PubMed ID: 23904277
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone treatment in pituitary insufficiency: selected cases of children with craniopharyngioma and medulloblastoma.
Kedzia A; Obara-Moszyńska M; Korman E; Rabska-Pietrzak B; Kopinski P; Trojan J; Goździcka-Józefiak A
Rocz Akad Med Bialymst; 2003; 48():28-33. PubMed ID: 14737937
[TBL] [Abstract][Full Text] [Related]
12. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database.
Gardner CJ; Mattsson AF; Daousi C; Korbonits M; Koltowska-Haggstrom M; Cuthbertson DJ
Eur J Endocrinol; 2015 Apr; 172(4):371-81. PubMed ID: 25583905
[TBL] [Abstract][Full Text] [Related]
13. Postoperative pituitary hormonal disturbances and hormone replacement therapy time and dosage in children with craniopharyngiomas.
Li GM; Sun XJ; Shao P
Chin Med J (Engl); 2008 Oct; 121(20):2077-82. PubMed ID: 19080279
[TBL] [Abstract][Full Text] [Related]
14. Acute pancreatitis in a girl with panhypopituitarism due to craniopharyngioma on growth hormone treatment. A combination of risk factors.
Faienza MF; Delvecchio M; Indrio F; Francavilla R; Acquafredda A; Cavallo L
Horm Res; 2009; 71(6):372-5. PubMed ID: 19506396
[TBL] [Abstract][Full Text] [Related]
15. [The evaluation of the influence of growth hormone therapy on growing process and metabolic functions in patients after treatment of craniopharyngioma].
Okońska M; Birkholz D; Korpal-Szczyrska M; Adamkiewicz-Drozyńska E; Alska A; Magnuszewska H
Pediatr Endocrinol Diabetes Metab; 2010; 16(1):19-24. PubMed ID: 20529601
[TBL] [Abstract][Full Text] [Related]
16. Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
Chung TT; Evanson J; Walker D; Akker SA; Besser GM; Monson JP; Grossman AB; Drake WM
Clin Endocrinol (Oxf); 2008 Jun; 68(6):965-9. PubMed ID: 18031317
[TBL] [Abstract][Full Text] [Related]
17. New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.
Krzyzanowska-Mittermayer K; Mattsson AF; Maiter D; Feldt-Rasmussen U; Camacho-Hübner C; Luger A; Abs R
J Clin Endocrinol Metab; 2018 Feb; 103(2):523-531. PubMed ID: 29228199
[TBL] [Abstract][Full Text] [Related]
18. Medium and long-term outcome of growth hormone therapy in growth hormone deficient adults.
Fideleff HL; Boquete H; Giaccio A; Sobrado P;
Medicina (B Aires); 2006; 66(4):296-302. PubMed ID: 16977963
[TBL] [Abstract][Full Text] [Related]
19. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
Chung TT; Drake WM; Evanson J; Walker D; Plowman PN; Chew SL; Grossman AB; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2005 Sep; 63(3):274-9. PubMed ID: 16117814
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the -629C>A CETP promoter polymorphism in GH-receiving hypopituitary patients.
Dullaart RP; Schols JL; van der Steege G; Zelissen PM; Sluiter WJ; van Beek AP
Clin Endocrinol (Oxf); 2008 Sep; 69(3):359-66. PubMed ID: 18221399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
